Cargando…

Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113–122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice

Mimetic peptides are potential therapeutic agents for atherosclerosis. d-[113–122]apolipoprotein (apo) J (d-[113–122]apoJ) is a 10-residue peptide that is predicted to form a class G* amphipathic helix 6 from apoJ; it shows anti-inflammatory and anti-atherogenic properties. In the present study, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivas-Urbina, Andrea, Rull, Anna, Aldana-Ramos, Joile, Santos, David, Puig, Nuria, Farre-Cabrerizo, Nuria, Benitez, Sonia, Perez, Antonio, de Gonzalo-Calvo, David, Escola-Gil, Joan Carles, Julve, Josep, Ordoñez-Llanos, Jordi, Sanchez-Quesada, Jose Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356811/
https://www.ncbi.nlm.nih.gov/pubmed/32485898
http://dx.doi.org/10.3390/biom10060829
_version_ 1783558568209809408
author Rivas-Urbina, Andrea
Rull, Anna
Aldana-Ramos, Joile
Santos, David
Puig, Nuria
Farre-Cabrerizo, Nuria
Benitez, Sonia
Perez, Antonio
de Gonzalo-Calvo, David
Escola-Gil, Joan Carles
Julve, Josep
Ordoñez-Llanos, Jordi
Sanchez-Quesada, Jose Luis
author_facet Rivas-Urbina, Andrea
Rull, Anna
Aldana-Ramos, Joile
Santos, David
Puig, Nuria
Farre-Cabrerizo, Nuria
Benitez, Sonia
Perez, Antonio
de Gonzalo-Calvo, David
Escola-Gil, Joan Carles
Julve, Josep
Ordoñez-Llanos, Jordi
Sanchez-Quesada, Jose Luis
author_sort Rivas-Urbina, Andrea
collection PubMed
description Mimetic peptides are potential therapeutic agents for atherosclerosis. d-[113–122]apolipoprotein (apo) J (d-[113–122]apoJ) is a 10-residue peptide that is predicted to form a class G* amphipathic helix 6 from apoJ; it shows anti-inflammatory and anti-atherogenic properties. In the present study, we analyzed the effect of d-[113–122]apoJ in low-density lipoprotein receptor knockout mice(LDLR-KO) on the development of atherosclerosis and lipoprotein function. Fifteen-week-old female LDLR-KO mice fed an atherogenic Western-type diet were treated for eight weeks with d-[113–122]apoJ peptide, a scrambled peptide, or vehicle. Peptides were administered subcutaneously three days per week (200 µg in 100 µL of saline). After euthanasia, blood and hearts were collected and the aortic arch was analyzed for the presence of atherosclerotic lesions. Lipoproteins were isolated and their composition and functionality were studied. The extent of atherosclerotic lesions was 43% lower with d-[113–122]apoJ treatment than with the vehicle or scramble. The lipid profile was similar between groups, but the high-density lipoprotein (HDL) of d-[113–122]apoJ-treated mice had a higher antioxidant capacity and increased ability to promote cholesterol efflux than the control group. In addition, low-density lipoprotein (LDL) from d-[113–122]apoJ-treated mice was more resistant to induced aggregation and presented lower electronegativity than in mice treated with d-[113–122]apoJ. Our results demonstrate that the d-[113–122]apoJ peptide prevents the extent of atherosclerotic lesions, which could be partially explained by the improvement of lipoprotein functionality.
format Online
Article
Text
id pubmed-7356811
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73568112020-07-22 Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113–122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice Rivas-Urbina, Andrea Rull, Anna Aldana-Ramos, Joile Santos, David Puig, Nuria Farre-Cabrerizo, Nuria Benitez, Sonia Perez, Antonio de Gonzalo-Calvo, David Escola-Gil, Joan Carles Julve, Josep Ordoñez-Llanos, Jordi Sanchez-Quesada, Jose Luis Biomolecules Article Mimetic peptides are potential therapeutic agents for atherosclerosis. d-[113–122]apolipoprotein (apo) J (d-[113–122]apoJ) is a 10-residue peptide that is predicted to form a class G* amphipathic helix 6 from apoJ; it shows anti-inflammatory and anti-atherogenic properties. In the present study, we analyzed the effect of d-[113–122]apoJ in low-density lipoprotein receptor knockout mice(LDLR-KO) on the development of atherosclerosis and lipoprotein function. Fifteen-week-old female LDLR-KO mice fed an atherogenic Western-type diet were treated for eight weeks with d-[113–122]apoJ peptide, a scrambled peptide, or vehicle. Peptides were administered subcutaneously three days per week (200 µg in 100 µL of saline). After euthanasia, blood and hearts were collected and the aortic arch was analyzed for the presence of atherosclerotic lesions. Lipoproteins were isolated and their composition and functionality were studied. The extent of atherosclerotic lesions was 43% lower with d-[113–122]apoJ treatment than with the vehicle or scramble. The lipid profile was similar between groups, but the high-density lipoprotein (HDL) of d-[113–122]apoJ-treated mice had a higher antioxidant capacity and increased ability to promote cholesterol efflux than the control group. In addition, low-density lipoprotein (LDL) from d-[113–122]apoJ-treated mice was more resistant to induced aggregation and presented lower electronegativity than in mice treated with d-[113–122]apoJ. Our results demonstrate that the d-[113–122]apoJ peptide prevents the extent of atherosclerotic lesions, which could be partially explained by the improvement of lipoprotein functionality. MDPI 2020-05-29 /pmc/articles/PMC7356811/ /pubmed/32485898 http://dx.doi.org/10.3390/biom10060829 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rivas-Urbina, Andrea
Rull, Anna
Aldana-Ramos, Joile
Santos, David
Puig, Nuria
Farre-Cabrerizo, Nuria
Benitez, Sonia
Perez, Antonio
de Gonzalo-Calvo, David
Escola-Gil, Joan Carles
Julve, Josep
Ordoñez-Llanos, Jordi
Sanchez-Quesada, Jose Luis
Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113–122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice
title Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113–122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice
title_full Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113–122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice
title_fullStr Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113–122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice
title_full_unstemmed Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113–122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice
title_short Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113–122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice
title_sort subcutaneous administration of apolipoprotein j-derived mimetic peptide d-[113–122]apoj improves ldl and hdl function and prevents atherosclerosis in ldlr-ko mice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356811/
https://www.ncbi.nlm.nih.gov/pubmed/32485898
http://dx.doi.org/10.3390/biom10060829
work_keys_str_mv AT rivasurbinaandrea subcutaneousadministrationofapolipoproteinjderivedmimeticpeptided113122apojimprovesldlandhdlfunctionandpreventsatherosclerosisinldlrkomice
AT rullanna subcutaneousadministrationofapolipoproteinjderivedmimeticpeptided113122apojimprovesldlandhdlfunctionandpreventsatherosclerosisinldlrkomice
AT aldanaramosjoile subcutaneousadministrationofapolipoproteinjderivedmimeticpeptided113122apojimprovesldlandhdlfunctionandpreventsatherosclerosisinldlrkomice
AT santosdavid subcutaneousadministrationofapolipoproteinjderivedmimeticpeptided113122apojimprovesldlandhdlfunctionandpreventsatherosclerosisinldlrkomice
AT puignuria subcutaneousadministrationofapolipoproteinjderivedmimeticpeptided113122apojimprovesldlandhdlfunctionandpreventsatherosclerosisinldlrkomice
AT farrecabrerizonuria subcutaneousadministrationofapolipoproteinjderivedmimeticpeptided113122apojimprovesldlandhdlfunctionandpreventsatherosclerosisinldlrkomice
AT benitezsonia subcutaneousadministrationofapolipoproteinjderivedmimeticpeptided113122apojimprovesldlandhdlfunctionandpreventsatherosclerosisinldlrkomice
AT perezantonio subcutaneousadministrationofapolipoproteinjderivedmimeticpeptided113122apojimprovesldlandhdlfunctionandpreventsatherosclerosisinldlrkomice
AT degonzalocalvodavid subcutaneousadministrationofapolipoproteinjderivedmimeticpeptided113122apojimprovesldlandhdlfunctionandpreventsatherosclerosisinldlrkomice
AT escolagiljoancarles subcutaneousadministrationofapolipoproteinjderivedmimeticpeptided113122apojimprovesldlandhdlfunctionandpreventsatherosclerosisinldlrkomice
AT julvejosep subcutaneousadministrationofapolipoproteinjderivedmimeticpeptided113122apojimprovesldlandhdlfunctionandpreventsatherosclerosisinldlrkomice
AT ordonezllanosjordi subcutaneousadministrationofapolipoproteinjderivedmimeticpeptided113122apojimprovesldlandhdlfunctionandpreventsatherosclerosisinldlrkomice
AT sanchezquesadajoseluis subcutaneousadministrationofapolipoproteinjderivedmimeticpeptided113122apojimprovesldlandhdlfunctionandpreventsatherosclerosisinldlrkomice